Cargando…

Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis

Detalles Bibliográficos
Autores principales:	Lai, Tianwen, Wang, Shaobin, Xu, Zhiwei, Zhang, Chao, Zhao, Yun, Hu, Yue, Cao, Chao, Ying, Songmin, Chen, Zhihua, Li, Wen, Wu, Bin, Shen, Huahao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Corrigenda
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536535/ https://www.ncbi.nlm.nih.gov/pubmed/26272505 http://dx.doi.org/10.1038/srep09548

Ejemplares similares

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic
por: Kirchnerová, Olga Růžičková, et al.
Publicado: (2018)

The “real-world” effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study
por: Siracká, Simona, et al.
Publicado: (2022)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
por: Sztafińska, Anna, et al.
Publicado: (2021)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
por: Wang, Xiaohui, et al.
Publicado: (2017)

Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
por: Tsai, Ming-Ju, et al.
Publicado: (2016)

Corrigendum: Paper-based CRP Monitoring Devices
por: Lin, Shang-Chi, et al.
Publicado: (2017)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Corrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
Publicado: (2021)

Corrigendum: Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy
por: Zhang, Xiaoxin, et al.
Publicado: (2016)

Corrigendum: Intestinal microbiome in children with severe and complicated acute viral gastroenteritis
por: Chen, Shih-Yen, et al.
Publicado: (2017)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics
por: Sintobin, Ina, et al.
Publicado: (2015)

Corrigendum: Safety and anti-hyperglycemic efficacy of various tea types in mice
por: Han, Manman, et al.
Publicado: (2016)

Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014)

Corrigendum to: ASTRAL-Pro: Quartet-Based Species-Tree Inference despite Paralogy
por: Zhang, Chao, et al.
Publicado: (2021)

Corrigendum: Photon-phonon Interaction in a Microfiber Induced by Optical and Electrostrictive Forces
por: Shi, Yun-chao, et al.
Publicado: (2017)

Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Publicado: (2021)

IL-17-Mediated Inflammation Promotes Cigarette Smoke-Induced Genomic Instability
por: Cao, Chao, et al.
Publicado: (2021)

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Corrigendum: Manipulating the banana rhizosphere microbiome for biological control of Panama disease
por: Xue, Chao, et al.
Publicado: (2015)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Corrigendum: Efficient visible-light photocatalytic degradation system assisted by conventional Pd catalysis
por: Yu, Yanlong, et al.
Publicado: (2018)

Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis
por: Cao, Chao, et al.
Publicado: (2016)

Corrigendum
Publicado: (2006)

Corrigendum
Publicado: (2006)

Corrigendum
Publicado: (2011)

Corrigendum
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ia0ctuphn5ip6hivbf3u1mliaf